Xin Sheng-Chang, Zhao Yan-Qiu, Li Song, Lin Shuo, Zhong Han-Bing
Laboratory of Chemical Genomics, School of Chemical Biology and Biotechnology, Peking University Shenzhen Graduate School, Shenzhen 518055, China.
Yi Chuan. 2012 Sep;34(9):1144-52.
Due to its small size, fast external development, transparent embryos, and amenability to genetic analysis, zebrafish has become an ideal vertebrate animal model. In addition to studies in genetics and developmental biology, zebrafish has also been widely used in human disease modeling and drug screening. As a small whole-organism model, zebrafish can be used to comprehensively test and evaluate the activity and side effect of a compound at the same time, fulfilling high content screening. Recently, new zebrafish disease models and screening technologies have been developed. A number of active compounds were identified and most of them have similar functions in mammal models. One compound prostaglandin E2 has been subjected to clinical trial to test if it can promote the growth of umbilical cord blood units after transplantation. Another compound leflunomide has also been approved in clinical trial to cure melanoma in combination with vemurafenib. These findings demonstrate that zebrafish model is appropriate for drug screening. This review summarizes the unique features of zebrafish model and the recent progresses of zebrafish based drug screening.
由于体型小、外部发育快、胚胎透明且易于进行遗传分析，斑马鱼已成为理想的脊椎动物模型。除了用于遗传学和发育生物学研究外，斑马鱼还被广泛应用于人类疾病建模和药物筛选。作为一种小型的整体生物模型，斑马鱼可用于同时全面测试和评估化合物的活性及副作用，实现高内涵筛选。近年来，新的斑马鱼疾病模型和筛选技术不断涌现。一些活性化合物被鉴定出来，其中大多数在哺乳动物模型中具有相似功能。一种化合物前列腺素E2已进入临床试验阶段，以测试其是否能促进移植后脐带血单位的生长。另一种化合物来氟米特也已在临床试验中获批，可与维莫非尼联合用于治疗黑色素瘤。这些发现表明斑马鱼模型适用于药物筛选。本综述总结了斑马鱼模型的独特特征以及基于斑马鱼的药物筛选的最新进展。
